Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2004

View Archived Issues

Preclinical evidence suggests a role for Flt3-ligand in the treatment of diabetes

Antiarrhythmic effects of ranolazine in canine left ventricle preparations

Benefits of atorvastatin in the prevention of recurrent cardiovascular events after ACS

The Medicines Company updates second quarter developments

Key development projects at Roche made significant progress in first half of 2004

Novel series of MC4 receptor agonists highlighted at recent ACS meeting

Preliminary data on the efficacy of a tenofovir/emtricitabine combination in HIV-infected patients

Long-term efficacy of efavirenz-containing antiretroviral regimens in HIV infection

Cannabinoids found to improve urge incontinence in MS patients

Good safety profile reported for darifenacin in OAB

Takeda develops new metastin derivatives for preventing cancer metastasis

New mitotic kinesin KSP inhibitors discovered by Merck researchers

Neurocrine presents new melanocortin MC3/MC4 modulators and their use

Novel MIF ligands and their use covered by Takeda patent

Novel 17beta-HSD-3 inhibitors and their use claimed by Schering-Plough

New S1P1/Edg1 agonists developed by Merck scientists

MitoKor presents adenine nucleotide translocase ligands and their use

Long-term improvement of urinary incontinence achieved with solifenacin

Imvamune progresses during first half of 2004

MedImmune terminates rheumatoid arthritis and psoriasis trials for Vitaxin

Phase I/II trial for EW-A-401

IC-MedTech licenses Apatone

Vaccine programs progress at Sinovac

Scandinavian phase II trial of Alpharadin extended to U.K.

FDA approval for Parcopa

Yamanouchi submits YM-905 for approval in Japan

North American Scientific to end Theseus Imaging subsidiary operations

EP-013420 enters phase I study

Oralin submitted for approval in Ecuador

AVI to test AVI-4020 in West Nile virus neuroinvasive disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...